Big pharma M&A: AstraZeneca-Bristol Myers Squibb talks

What happened: AstraZeneca, the U.K.'s largest drugmaker, has reportedly been in talks with U.S. peer Bristol Myers Squibb over a potential megadeal that could value the combined entity at roughly $400 billion. The Financial Times first reported these discussions, which, if completed, would create one of the world's largest drugmakers. AstraZeneca shares dropped by up to 7% following the reports, while Bristol Myers Squibb shares were relatively unchanged.

Market impact: The pharmaceutical sector is affected, with AstraZeneca's stock price taking a hit due to the proposed merger. The significant size of the deal and the potential synergies could reshape the competitive landscape in the pharmaceutical industry. Investors are likely reassessing their positions in both companies, with AstraZeneca's valuation repricing reflecting the uncertainty around the deal's outcome.

What to watch next: AstraZeneca's next earnings call on May 5, 2023, could provide more color on the company's strategic direction and potential M&A activity. Additionally, any official announcements or denials regarding the merger talks from either AstraZeneca or Bristol Myers Squibb will significantly influence the narrative's evolution. Lastly, regulatory scrutiny, particularly from antitrust authorities, will play a crucial role in determining the deal's fate.